WCN26-5648 EVIDENCE-BASED POSITIONING OF SGLT2IS AND GLP-1 RAS IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES AND OVERWEIGHT/OBESITY: A SYSTEMATIC LITERATURE REVIEW

Read full text Summarise with VIRAT
Authors: Yehuda Handelsman, Alice Y. Y. Cheng, Gian Paolo Fadini, Pam R. Kushner, Fabrice Bonnet, Paola Fioretto, Takashi Kadowaki, Naresh Kanumilli, Xavier Cos, Thomas Frese, Linong Ji, Molly Murton
+3 more Simon Foulcer, Surendra Pentakota, Peter R Rossing
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) is a leading cause of premature death globally and is closely linked with type 2 diabetes (T2D) and obesity. While both sodium-glucose co-transporter protein 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown kidney benefit and are recommended by major guidelines in this population, there remains a lack of clarity on their foundational versus adjunctive role. This systematic literature review (SLR) aimed to identify evidence on comparisons (direct or indirect), combinations, or sequencing of SGLT2is and GLP-1 RAs in populations or subgroups of adults with CKD and T2D with or without overweight/obesity.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104628–104628
Publication date
25 March 2026
Language
EN